New treatments like dotinurad provide safer, more effective solutions for millions battling gout and hyperuricemia.

XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding ...

Febuxostat is a second-line option for patients with gout who are unable to take allopurinol due to hypersensitivity, intolerance, or lack of efficacy in achieving a target serum uric acid ...

Am J Health Syst Pharm. 2011;68(5):389-398. Gout flares typically begin abruptly, with red, hot, or tender joints. Individuals may also be febrile during gouty attacks. Attacks may be ...

About Hyperuricemia, Gout and Health Consequences The breakdown of nucleotides ... however 3 to 5% of patients cannot tolerate allopurinol. An alternative XOI, Febuxostat, launched in the US in 2009 ...

XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. The company is actively involved in creating ...

Addressable Gout Market Opportunity In North America ... An alternative XOI, Febuxostat, launched in the US in 2009 with the hope of treating allopurinol intolerant patients, however while ...